HBM BioCapital II LP 3
3 · Allena Pharmaceuticals, Inc. · Filed Nov 1, 2017
Insider Transaction Report
Form 3
HBM BioCapital II LP
10% Owner
Holdings
Series B Convertible Preferred Stock
[F1]→ Common Stock (1,426,061 underlying)Series C Convertible Preferred Stock
[F2]→ Common Stock (140,841 underlying)
Footnotes (2)
- [F1]The Series B Convertible Preferred Stock is convertible into Common Stock of the Issuer on a 4.174-to-1 basis at any time at the holder's election, and has no expiration. The Series B Convertible Preferred Stock will automatically convert into Common Stock of the Issuer upon the closing of the Issuer's initial public offering.
- [F2]The Series C Convertible Preferred Stock is convertible into Common Stock of the Issuer on a 4.174-to-1 basis at any time at the holder's election, and has no expiration. The Series C Convertible Preferred Stock will automatically convert into Common Stock of the Issuer upon the closing of the Issuer's initial public offering.
Signature
/s/ Matthew Hague (Authorized Signatory)|2017-11-01